References of "COUCKE, Philippe"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPrognostic factors in urothelial renal pelvis and ureter tumors: A multicenter Rare Cancer Network study
Ozsahin, Mahmut; Zouhair, Abderrahim; Villà, S. et al

in International Journal of Radiation, Oncology, Biology, Physics (1997), 3(2(supp)), 290

Detailed reference viewed: 5 (2 ULg)
Full Text
Peer Reviewed
See detailAntitumor and radiosensitizing effects of (E)-2'-Deoxy-2'-(Fluoromethylene) cytidine, a novel inhibior of ribonucleotide diphosphate reductase on human colon carcinoma xenografts in nude mice.
Sun, Lin-Quan; Li, Ye-Xiong; Guillou, Louis et al

in Cancer Research (1997), 57

Antitumor and radiosensitizing effects of (E).2'-deoxy.2'-(fluromethyl ene) cytidine (FMdC), a novel inhibitor of ribonucleotide reductase, were evaluated on nude mice bearing s.c. xenografts and liver ... [more ▼]

Antitumor and radiosensitizing effects of (E).2'-deoxy.2'-(fluromethyl ene) cytidine (FMdC), a novel inhibitor of ribonucleotide reductase, were evaluated on nude mice bearing s.c. xenografts and liver metastases of a human colon carcinoma. FMdC given once daily or twice weekly has a dose-dependent antitumor effect. The maximum tolerated dose In the mice was reached with 10 mgi'kg applied daily over 12 days. Twice weekly administration of FMdC reduced its toxicity but lowered the antitumor effect. Treatment of preestablished liver micrometastases obtained via intrasplenic injection of tumor cells, with 5 or 10 mgfkg FMdC, signifi candy prolonged the survival of the mice as compared to controls (P < 0.025 and P < 0.001, respectively). Ten mg/kg resulted in longer survival than S mg/kg FMdC (P < 0.05). Radiotherapy alone of s.c. xenografts (10 fractions over 12 days) yielded the radiation dose required to produce local tumor control in 50% of the treated mice (TCD@O)of 43.0 Gy. When combined with FMdC, TCDsawas reduced to 22.5 and 19.0 Gy at doses of 5 and 10 mg/kg given i.p. 1 h before each irradiation, respec tively. The corresponding enhancement ratios were 1.91 and 2.43, respec lively. FMdC produced moderate and reversible myelosuppression. When 5 mg/kg FMdC was combined with irradiation, there was no increased skin or hematological toxicity as compared to radiotherapy or FMdC alone. At the 10 mg/kg level, however, lower leukocyte counts were observed. These results show that FMdC appears to be a potent anticancer drug and radiosensitizer [less ▲]

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailRadiotherapie externe focalisee apres resection de metastase cerebrale unique: etude prospective de phase I-II
Zouhair; COUCKE, Philippe ULg; Douglas, Pelham et al

in Bulletin du Cancer. Radiothérapie : Journal de la Société Française du Cancer : Organe de la Société Française de Radiothérapie Oncologique (1997), 1

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailCell-line specific radiosensitizing effect of zalcitabine (DDC)
Coucke, Philippe ULg; Li, Ye-Xiong; Copaceanu, Marie-Laure et al

in Acta Oncologica (1997)

The potential of zalcitabine (ddC) to act as an ionizing radiation response modifier was tested on exponentially growing human cancer cells in vitro. Two human cell lines, WiDr (colon) and MCF-7 (breast ... [more ▼]

The potential of zalcitabine (ddC) to act as an ionizing radiation response modifier was tested on exponentially growing human cancer cells in vitro. Two human cell lines, WiDr (colon) and MCF-7 (breast) were exposed to ddC at 10 p M concentration for various lengths of tide (18, 24, 48 and 72 h). On the WiDr cell line the dual effect of concentration and duration of exposure prior to irradiation was investigated. Experimental endpoints were clonogenicity and viability, as measured by colony formation assay (CFA) and MTT assay respectively. The impact on cell-cycle distribution prior to irradiation was assessed by flow cytometry using a double labeling technique (propidium iodide and bromodeoxyuridine pulse label). A significant reduction in surviving fraction and viability was observed for WiDr-cells irradiated after pre-exposure to 10 pM for 18, 48 and 72 h as compared to corresponding irradiated controls. At lower concentrations (1 and 5 pM), the radiosensitizing effect was only significant after a 72-h exposure (assessed by CFA). For MCF-7, ddC induced a significant modification of the dose response only with 24 and 48 h preincubation. However, the overall effect was less pronounced as compared to WiDr. Cell-cycle analysis showed accumulation in S-phase, 48 and 72 h after treatment with 10 pM ddC in the WiDr cells, with a progressive shift to late S-phase as shown by the biparametric analysis. The degree of radiosensitization is cell-line dependent with the most important sensitization observed on the most <<radioresistant cell line>>, ix., the cell line with the lowest alpha value and highest SF 2 (WiDr). For WiDr, radiosensitization by ddC depends on the duration of exposure and the concentration of the drug. Received 29 February 1996 Accepted 10 December 1996 [less ▲]

Detailed reference viewed: 32 (2 ULg)
See detailPotential doubling time determination in a multicentre clinical study.
COUCKE, Philippe ULg

in Abstract book (1996)

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailEffect of total treatment time on event-free survival in carcinoma of the cervix
Delaloye, J-F; COUCKE, Philippe ULg; Pampallona, S et al

in Gynecologic Oncology (1996), 60

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailYounger age as a bad prognostic factor in patients with carcinoma of the cervix.
Delaloye, J-F; Pampallona, S; COUCKE, Philippe ULg et al

in European Journal of Obstetrics & Gynecology & Reproductive Biology (1996)

Objective: To verify the influence of age on the prognosis of cervix carcinoma. Study design: Five hundred and sixty eight patients treated for a FIGO stage IB-IVA with radical irradiation in the Centre ... [more ▼]

Objective: To verify the influence of age on the prognosis of cervix carcinoma. Study design: Five hundred and sixty eight patients treated for a FIGO stage IB-IVA with radical irradiation in the Centre Hospitalier Universitaire Vaudois of Lausanne were subdivided according to the following age categories: _<45, 46-60, 61-69 and > 70 years. Taking the 46-60 years age group as the reference, the hazard ratios (HR) of death and corresponding 95% confidence intervals (95% CI) were estimated by means of a Cox multivariate analysis. Results: The 5-year survival rates were, respectively, 57%, 67%, 60% and 45%. For the youngest women the risk of death was significantly increased (HR = 2.00, 95% CI [1.32-3.00]) and was even more accentuated in advanced stages. Conclusion: Age under 45 years is a bad prognostic factor in carcinoma of the cervix. [less ▲]

Detailed reference viewed: 19 (2 ULg)
Full Text
Peer Reviewed
See detailNew ribonucleotide reductase inhibitor, (E)-2′-deoxy-(fluromethylene) cytidine, acts as a radiosensitizer on human colon and cervix cancer cell lines
Coucke, Philippe ULg; LI, XY; Cottin, E et al

in Radiotherapy & Oncology (1996), 40(Supplément 1), 135

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailWhat about lorisk Figo Stage Ia and Ib, G1-G2 endometrial adenocarcinoma ?
Delaloye, J-F; Megalo; COUCKE, Philippe ULg et al

in Radiotherapy & Oncology (1996), 43(Supp 1), 6

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailRadiosensitization in vitro by (E)-2′-(fluoromethylene)-deoxy-cytidine (FMdC), pentoxifylline (PTX) or a combination
Li; COUCKE, Philippe ULg; Paschoud et al

in International Journal of Radiation, Oncology, Biology, Physics (1996), 36(1 (supp1)), 383

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailMort mitotique ou mort apoptotique par irradiation : Même combat ?
Coucke, Philippe ULg; ZOUHAIR

in Médecine et Hygiène (1996), 54(2121), 1241-1245

La mort cellulaire active (apoptose) est un phénomène ubiquitaire dans les organismes multicellulaires. L'apoptose joue un rôle essentiel dans la genèse d'un cancer et dans la réponse au traitement ... [more ▼]

La mort cellulaire active (apoptose) est un phénomène ubiquitaire dans les organismes multicellulaires. L'apoptose joue un rôle essentiel dans la genèse d'un cancer et dans la réponse au traitement oncologique. Les radiations ionisantes sont capables d'induire une mort mitotique et une mort apoptotique. Nous définissons les caractéristiques radiobiologiques de chaque type de mort cellulaire et situons l'importance de l'apoptose pour la réponse tumorale aux radiations ionisantes. La modulation de ce «suicide cellulaire» devrait permettre une amélioration de l'index thérapeutique mais ceci implique une connaissance approfondie des mécanismes qui règlent l'apoptose [less ▲]

Detailed reference viewed: 89 (0 ULg)
Full Text
Peer Reviewed
See detailDoes proliferation status predict radiation response in human tumors?
Coucke, Philippe ULg

in Radiotherapy & Oncology (1996), 40(Supp 1), 55

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailT92-0045: Interlaboratory quality control on Tpot measurements
Coucke, Philippe ULg; Beer, K.; Bernier, J. et al

in International Journal of Radiation, Oncology, Biology, Physics (1996), 36(1(supp1)), 384

Detailed reference viewed: 13 (3 ULg)
Full Text
See detailChemical Modifiers of Cancer Treatment
Coucke, Philippe ULg; Workman, Paul; Coleman, Norman

in Chemical Modifiers of Cancer Treatment (1995, August 22)

Detailed reference viewed: 2 (1 ULg)
Full Text
See detailMolecular basis of radioresistance
COUCKE, Philippe ULg

Doctoral thesis (1995)

Detailed reference viewed: 32 (15 ULg)
Full Text
Peer Reviewed
See detailCombined radiotherapy and radioimmotherapy of human colon carcinoma grafted in nude mice.
Buchegger, F; Rojas, A; Delaloye, A et al

in Cancer Research (1995), 55

The effect of combined radioimmunotherapy (RIT) and fractionated external beam radiotherapy (RT) was assessed in two human colon cancer xenografts, Col 12 and LS174T in nude mice. These tumors were ... [more ▼]

The effect of combined radioimmunotherapy (RIT) and fractionated external beam radiotherapy (RT) was assessed in two human colon cancer xenografts, Col 12 and LS174T in nude mice. These tumors were selected for being resistant to RIT alone, as is usually the case in the clinical situation. Tumor-bearing mice were treated with a combination of five X-ray fractions over 5 days followed by RIT with two doses of 1.5 mCi 131I-labeled anticarcinoembryonic antigen monoclonal antibody F(ab')2. In Col 12 and LS174T, RIT alone achieved a regrowth delay similar to that of fractionated RT with total doses of 28 and 26 Gy, respectively. In both tumor types, an additive therapeutic effect, measured as increased regrowth delay or local control, was observed when combining RT of different dose levels with RIT. Normal tissue responses were assessed by monitoring acute peak skin reactions and blood cell count. Bone marrow depression for the combination treatment was similar to that of RIT alone; relative to skin, at equitoxic levels, no mice bearing Col 12 tumors were locally controlled with a 32 Gy RT dose alone, while this RT combined with RIT gave a local control of 100%. These studies show a therapeutic benefit when external beam RT is combined with RIT. [less ▲]

Detailed reference viewed: 14 (5 ULg)
Full Text
Peer Reviewed
See detailAzidothymidine as a potential modifier of radiation-reponse
Copaceanu, M-L; COUCKE, Philippe ULg; Cottin, E et al

in Acta Oncologica (1995)

Abstract The potential effect of AZT as a thymidine analogue on radiation response in vitro was investigated. Two human cell lines (WiDr and HeLa) were used. The effect of 10 μM AZT on exponentially ... [more ▼]

Abstract The potential effect of AZT as a thymidine analogue on radiation response in vitro was investigated. Two human cell lines (WiDr and HeLa) were used. The effect of 10 μM AZT on exponentially growing cells was studied after different exposure times (24, 48 and 72 h). The surviving fraction (clonogenic assay) or metabolic activity (MTT assay) after irradiation of AZT-exposed cells, was compared to unexposed irradiated controls. Flow cytometry was used to assess the cell-cycle effect of pre-exposure of exponentially growing cells to AZT. AZT had a radioprotective effect for all experimental time points as far as WiDr was concerned. For HeLa the effect was significant at 24 h. Cell-cycle analysis showed a significant accumulation in S-phase at 72 h for WiDr. For HeLa there was a significant accumulation in S-phase at 48 h. We conclude that under the reported experimental conditions, AZT as a thymidine analogue seems to reduce the cytotoxic effect of irradiation. [less ▲]

Detailed reference viewed: 18 (5 ULg)
Full Text
Peer Reviewed
See detailThe rationale to switch from postoperative hyperfractionated accelerated radiotherapy to preoperative hyperfractionated accelerated radiotherapy in rectal cancer
COUCKE, Philippe ULg; Sartorelli, B; Cuttat, J-F et al

in International Journal of Radiation, Oncology, Biology, Physics (1995), 32(1), 181-188

To demonstrate the feasibility of preoperative Hyperfractionated Accelerated Radio Therapy (preop-HART) ini rectal cancer and to explain the rationales to switch from postoperative HART to preoperative ... [more ▼]

To demonstrate the feasibility of preoperative Hyperfractionated Accelerated Radio Therapy (preop-HART) ini rectal cancer and to explain the rationales to switch from postoperative HART to preoperative HART. View the MathML source: Fifty-two consecutive patients were introduced in successive Phase I trials since 1989. In trial 89-01, postoperative HART (48 Gy in 3 weeks) was applied in 20 patients. In nine patients with locally advanced rectal cancer, considered unresectable by the surgeon, 32 Gy in 2 weeks was applied prior to surgery (trial 89-02). Sicne 1991, 41.6 Gy in 2.5 weeks has been applied preoperative to 23 patients with T3—T4 any N recatl cancer immediately followed by surgery (trial 91-01). All patients were irradiated at the department of radiation-oncology with a four-field box technique (1.6 Gy twice a day and with at least a 6-h interval between fractions). The minimal accelerating potential was 6 MV. Acute toxicity was scored according to the World Health Organization (WHO for skin and small bowel) and the Radiation Therapy Oncology Group criteria (RTOG for bladder). This was done weekly during treatment and every 3 months thereafter. Small bowel volume was estimated by a modified “Gallagher's” method. View the MathML source: Acute toxicity was acceptable both in postoperative setup. The mean acute toxicity was significantly lower in trial 91-01 compared to 89-01. This difference was due to the smaller amount of small bowel in irradiation field and lower total dose in trial 91-01. Moreover, there was a significantly reduced delay between surgery and radiotherapy favoring trial 91-01 (median delay 4 days compared to 46 days in trial 89-01). Nearly all patients in trial 89-02 and 91-01 underwent surgery (31 out of 32; 97%). Resection margins were negative in 29 out of 32. Hospitalization duration in trial 91-01 was not significantly different from trial 89-01 (19 vs. 21 days, respectively). View the MathML source: Hyperfractionated accelerated radiotherapy immediately followed by surgery is feasible as far as acute toxicity is concerned. Preoperative HART is favored by a significantly lower acute toxicity related, in part, to a smaller amount of irradiated small bowel, and a shorter duration of the delay between radiotherapy and surgery. Moreover, the hospital stay after preoperative HART is not significantly increased [less ▲]

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailNausea and vomiting in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide.
Miralbell, R; COUCKE, Philippe ULg; Behrouz, F et al

in European Journal of Cancer Prevention (1995)

A prospective trial was performed to better assess the risk of nausea and vomiting and the rescue value of tropisetron (TRO), a 5HT3 receptor antagonist, in 88 patients undergoing fractionated ... [more ▼]

A prospective trial was performed to better assess the risk of nausea and vomiting and the rescue value of tropisetron (TRO), a 5HT3 receptor antagonist, in 88 patients undergoing fractionated radiotherapy to the abdomen or to large supradiaphragmatic fields and failing a first anti-emetic trial with metoclopramide (MET). Nausea was graded 0 (absent), 1 (mild), 2 (moderate) and 3 (severe). Nausea requiring anti-emetics (L grade 2) was present in 64% of the patients. MET was able to control nausea (I grade 1) in 26 of 58 patients (45%) who developed 1 grade 2 nausea during radiation treatment (2 patients vomiting without nausea included). 34 patients required TRO, and 31 experienced immediate relief. However, nausea (1 grade 2) recurred in 7 patients from 1 to 3 weeks after starting, TRO. Sex, age, field type and field size (cm*) did not influence the incidence and severity of nausea and vomiting. Only 24188 patients vomited after starting radiotherapy. MET helped to eliminate emesis in one third of these patients. TRO helped to control vomiting in 73% of the salvaged patients. Constipation was observed in 8 patients on TRO and was a reason to stop the medication in 4 cases. [less ▲]

Detailed reference viewed: 18 (4 ULg)